Xtandi fails a combo study, blocking a path to continued use for Pfizer, Astellas
One of the studies on the prostate cancer drug Xtandi that Pfizer inherited in its $14 billion buyout of Medivation has failed to deliver.
The pharma giant and its partners at Astellas say that Xtandi combined with J&J’s rival Zytiga and the steroid prednisone failed to bend the curve on progression-free survival for chemo-naive patients whose disease had progressed following treatment with Xtandi, compared with a group of patients treated with Zytiga and prednisone alone. The investigators had been looking for a rationale to continue treatment with Xtandi, which would have expanded its blockbuster market even further.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.